Ireland regulator reports manufacturing deficiency at Biocon's Bengaluru plant

One of the deficiencies is categorised as 'major' and is being addressed in consultation with the regulatory agency, says the company

May 03, 2022 11:00 pm | Updated 11:00 pm IST - New Delhi

Biotechnology major Biocon Biologics on Tuesday said Ireland's health regulator had reported some deficiencies in the manufacturing process at the company's plant in Bengaluru.

The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.

"The inspection report contains no 'critical' observations and only one of the deficiencies is categorised as 'major' which is being addressed expeditiously in consultation with the regulatory agency," the spokesperson added.

The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.

Biocon Biologics is a subsidiary of Biocon Ltd.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.